Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival

Amin Alousi, Tao Wang, Michael T. Hemmer, Stephen R. Spellman, Mukta Arora, Daniel R. Couriel, Joseph Pidala, Paolo Anderlini, Michael Boyiadzis, Christopher N. Bredeson, Jean Yves Cahn, Mitchell S. Cairo, Shahinaz M. Gadalla, Shahrukh K. Hashmi, Robert Peter Gale, Junya Kanda, Rammurti T. Kamble, Mohamed A. Kharfan-Dabaja, Mark R Litzow, Olle RingdenAyman A. Saad, Kirk R. Schultz, Leo F. Verdonck, Edmund K. Waller, Jean A. Yared, Shernan G. Holtan, Daniel J. Weisdorf

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Peripheral blood (PB) and bone marrow (BM) from unrelated donors can serve as a graft source for hematopoietic cell transplantation (HCT). Currently, PB is most commonly used in roughly 80% of adult recipients. Determining the long-term impact of graft source on outcomes would inform this decision. Data collected by the Center for International Blood and Marrow Transplant Research from 5200 adult recipients of a first HCT from an 8/8 or 7/8 HLA antigen-matched unrelated donor for treatment of acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome between 2001 and 2011 were analyzed to determine the impact of graft source on graft-versus-host disease (GVHD) relapse-free survival (GRFS), defined as freedom from grade III/IV acute GVHD, chronic GVHD requiring immunosuppressive therapy, relapse, and death, and overall survival. GRFS at 2 years was superior in BM recipients compared with PB recipients (16%; 95% confidence interval [CI], 14% to 18% versus 10%; 95% CI, 8% to 11%; P <.0001) in the 8/8 HLA-matched cohort and 7/8 HLA-matched cohort (11%; 95% CI, 8% to 14% versus 5%; 95% CI, 4% to 7%; P =.001). With 8/8 HLA-matched unrelated donors, overall survival at 5 years was superior in recipients of BM (43%; 95% CI, 40% to 46% versus 38%; 95% CI, 36% to 40%; P =.014). The inferior 5-year survival in the PB cohort was attributable to a higher frequency of deaths while in remission compared with the BM cohort. For recipients of 7/8 HLA-matched grafts, survival at 5 years was similar in BM recipients and PB recipients (32% versus 29%; P =.329). BM grafts are associated with improved long-term GRFS and overall survival in recipients of matched unrelated donor HCT and should be considered the unrelated allograft of choice, when available, for adults with acute leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome.

Original languageEnglish (US)
Pages (from-to)270-278
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume25
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Unrelated Donors
Graft vs Host Disease
Allografts
Bone Marrow
Recurrence
Confidence Intervals
Cell Transplantation
Transplants
Myelodysplastic Syndromes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia
Graft Survival
Immunosuppressive Agents
HLA Antigens
Disease-Free Survival
Therapeutics
Research

Keywords

  • bone marrow
  • peripheral blood
  • unrelated donor hematopoietic cell transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Peripheral Blood versus Bone Marrow from Unrelated Donors : Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. / Alousi, Amin; Wang, Tao; Hemmer, Michael T.; Spellman, Stephen R.; Arora, Mukta; Couriel, Daniel R.; Pidala, Joseph; Anderlini, Paolo; Boyiadzis, Michael; Bredeson, Christopher N.; Cahn, Jean Yves; Cairo, Mitchell S.; Gadalla, Shahinaz M.; Hashmi, Shahrukh K.; Gale, Robert Peter; Kanda, Junya; Kamble, Rammurti T.; Kharfan-Dabaja, Mohamed A.; Litzow, Mark R; Ringden, Olle; Saad, Ayman A.; Schultz, Kirk R.; Verdonck, Leo F.; Waller, Edmund K.; Yared, Jean A.; Holtan, Shernan G.; Weisdorf, Daniel J.

In: Biology of Blood and Marrow Transplantation, Vol. 25, No. 2, 01.02.2019, p. 270-278.

Research output: Contribution to journalArticle

Alousi, A, Wang, T, Hemmer, MT, Spellman, SR, Arora, M, Couriel, DR, Pidala, J, Anderlini, P, Boyiadzis, M, Bredeson, CN, Cahn, JY, Cairo, MS, Gadalla, SM, Hashmi, SK, Gale, RP, Kanda, J, Kamble, RT, Kharfan-Dabaja, MA, Litzow, MR, Ringden, O, Saad, AA, Schultz, KR, Verdonck, LF, Waller, EK, Yared, JA, Holtan, SG & Weisdorf, DJ 2019, 'Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival', Biology of Blood and Marrow Transplantation, vol. 25, no. 2, pp. 270-278. https://doi.org/10.1016/j.bbmt.2018.09.004
Alousi, Amin ; Wang, Tao ; Hemmer, Michael T. ; Spellman, Stephen R. ; Arora, Mukta ; Couriel, Daniel R. ; Pidala, Joseph ; Anderlini, Paolo ; Boyiadzis, Michael ; Bredeson, Christopher N. ; Cahn, Jean Yves ; Cairo, Mitchell S. ; Gadalla, Shahinaz M. ; Hashmi, Shahrukh K. ; Gale, Robert Peter ; Kanda, Junya ; Kamble, Rammurti T. ; Kharfan-Dabaja, Mohamed A. ; Litzow, Mark R ; Ringden, Olle ; Saad, Ayman A. ; Schultz, Kirk R. ; Verdonck, Leo F. ; Waller, Edmund K. ; Yared, Jean A. ; Holtan, Shernan G. ; Weisdorf, Daniel J. / Peripheral Blood versus Bone Marrow from Unrelated Donors : Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. In: Biology of Blood and Marrow Transplantation. 2019 ; Vol. 25, No. 2. pp. 270-278.
@article{176d65dd6f834090bef5981af02b0570,
title = "Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival",
abstract = "Peripheral blood (PB) and bone marrow (BM) from unrelated donors can serve as a graft source for hematopoietic cell transplantation (HCT). Currently, PB is most commonly used in roughly 80{\%} of adult recipients. Determining the long-term impact of graft source on outcomes would inform this decision. Data collected by the Center for International Blood and Marrow Transplant Research from 5200 adult recipients of a first HCT from an 8/8 or 7/8 HLA antigen-matched unrelated donor for treatment of acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome between 2001 and 2011 were analyzed to determine the impact of graft source on graft-versus-host disease (GVHD) relapse-free survival (GRFS), defined as freedom from grade III/IV acute GVHD, chronic GVHD requiring immunosuppressive therapy, relapse, and death, and overall survival. GRFS at 2 years was superior in BM recipients compared with PB recipients (16{\%}; 95{\%} confidence interval [CI], 14{\%} to 18{\%} versus 10{\%}; 95{\%} CI, 8{\%} to 11{\%}; P <.0001) in the 8/8 HLA-matched cohort and 7/8 HLA-matched cohort (11{\%}; 95{\%} CI, 8{\%} to 14{\%} versus 5{\%}; 95{\%} CI, 4{\%} to 7{\%}; P =.001). With 8/8 HLA-matched unrelated donors, overall survival at 5 years was superior in recipients of BM (43{\%}; 95{\%} CI, 40{\%} to 46{\%} versus 38{\%}; 95{\%} CI, 36{\%} to 40{\%}; P =.014). The inferior 5-year survival in the PB cohort was attributable to a higher frequency of deaths while in remission compared with the BM cohort. For recipients of 7/8 HLA-matched grafts, survival at 5 years was similar in BM recipients and PB recipients (32{\%} versus 29{\%}; P =.329). BM grafts are associated with improved long-term GRFS and overall survival in recipients of matched unrelated donor HCT and should be considered the unrelated allograft of choice, when available, for adults with acute leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome.",
keywords = "bone marrow, peripheral blood, unrelated donor hematopoietic cell transplant",
author = "Amin Alousi and Tao Wang and Hemmer, {Michael T.} and Spellman, {Stephen R.} and Mukta Arora and Couriel, {Daniel R.} and Joseph Pidala and Paolo Anderlini and Michael Boyiadzis and Bredeson, {Christopher N.} and Cahn, {Jean Yves} and Cairo, {Mitchell S.} and Gadalla, {Shahinaz M.} and Hashmi, {Shahrukh K.} and Gale, {Robert Peter} and Junya Kanda and Kamble, {Rammurti T.} and Kharfan-Dabaja, {Mohamed A.} and Litzow, {Mark R} and Olle Ringden and Saad, {Ayman A.} and Schultz, {Kirk R.} and Verdonck, {Leo F.} and Waller, {Edmund K.} and Yared, {Jean A.} and Holtan, {Shernan G.} and Weisdorf, {Daniel J.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.bbmt.2018.09.004",
language = "English (US)",
volume = "25",
pages = "270--278",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Peripheral Blood versus Bone Marrow from Unrelated Donors

T2 - Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival

AU - Alousi, Amin

AU - Wang, Tao

AU - Hemmer, Michael T.

AU - Spellman, Stephen R.

AU - Arora, Mukta

AU - Couriel, Daniel R.

AU - Pidala, Joseph

AU - Anderlini, Paolo

AU - Boyiadzis, Michael

AU - Bredeson, Christopher N.

AU - Cahn, Jean Yves

AU - Cairo, Mitchell S.

AU - Gadalla, Shahinaz M.

AU - Hashmi, Shahrukh K.

AU - Gale, Robert Peter

AU - Kanda, Junya

AU - Kamble, Rammurti T.

AU - Kharfan-Dabaja, Mohamed A.

AU - Litzow, Mark R

AU - Ringden, Olle

AU - Saad, Ayman A.

AU - Schultz, Kirk R.

AU - Verdonck, Leo F.

AU - Waller, Edmund K.

AU - Yared, Jean A.

AU - Holtan, Shernan G.

AU - Weisdorf, Daniel J.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Peripheral blood (PB) and bone marrow (BM) from unrelated donors can serve as a graft source for hematopoietic cell transplantation (HCT). Currently, PB is most commonly used in roughly 80% of adult recipients. Determining the long-term impact of graft source on outcomes would inform this decision. Data collected by the Center for International Blood and Marrow Transplant Research from 5200 adult recipients of a first HCT from an 8/8 or 7/8 HLA antigen-matched unrelated donor for treatment of acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome between 2001 and 2011 were analyzed to determine the impact of graft source on graft-versus-host disease (GVHD) relapse-free survival (GRFS), defined as freedom from grade III/IV acute GVHD, chronic GVHD requiring immunosuppressive therapy, relapse, and death, and overall survival. GRFS at 2 years was superior in BM recipients compared with PB recipients (16%; 95% confidence interval [CI], 14% to 18% versus 10%; 95% CI, 8% to 11%; P <.0001) in the 8/8 HLA-matched cohort and 7/8 HLA-matched cohort (11%; 95% CI, 8% to 14% versus 5%; 95% CI, 4% to 7%; P =.001). With 8/8 HLA-matched unrelated donors, overall survival at 5 years was superior in recipients of BM (43%; 95% CI, 40% to 46% versus 38%; 95% CI, 36% to 40%; P =.014). The inferior 5-year survival in the PB cohort was attributable to a higher frequency of deaths while in remission compared with the BM cohort. For recipients of 7/8 HLA-matched grafts, survival at 5 years was similar in BM recipients and PB recipients (32% versus 29%; P =.329). BM grafts are associated with improved long-term GRFS and overall survival in recipients of matched unrelated donor HCT and should be considered the unrelated allograft of choice, when available, for adults with acute leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome.

AB - Peripheral blood (PB) and bone marrow (BM) from unrelated donors can serve as a graft source for hematopoietic cell transplantation (HCT). Currently, PB is most commonly used in roughly 80% of adult recipients. Determining the long-term impact of graft source on outcomes would inform this decision. Data collected by the Center for International Blood and Marrow Transplant Research from 5200 adult recipients of a first HCT from an 8/8 or 7/8 HLA antigen-matched unrelated donor for treatment of acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome between 2001 and 2011 were analyzed to determine the impact of graft source on graft-versus-host disease (GVHD) relapse-free survival (GRFS), defined as freedom from grade III/IV acute GVHD, chronic GVHD requiring immunosuppressive therapy, relapse, and death, and overall survival. GRFS at 2 years was superior in BM recipients compared with PB recipients (16%; 95% confidence interval [CI], 14% to 18% versus 10%; 95% CI, 8% to 11%; P <.0001) in the 8/8 HLA-matched cohort and 7/8 HLA-matched cohort (11%; 95% CI, 8% to 14% versus 5%; 95% CI, 4% to 7%; P =.001). With 8/8 HLA-matched unrelated donors, overall survival at 5 years was superior in recipients of BM (43%; 95% CI, 40% to 46% versus 38%; 95% CI, 36% to 40%; P =.014). The inferior 5-year survival in the PB cohort was attributable to a higher frequency of deaths while in remission compared with the BM cohort. For recipients of 7/8 HLA-matched grafts, survival at 5 years was similar in BM recipients and PB recipients (32% versus 29%; P =.329). BM grafts are associated with improved long-term GRFS and overall survival in recipients of matched unrelated donor HCT and should be considered the unrelated allograft of choice, when available, for adults with acute leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome.

KW - bone marrow

KW - peripheral blood

KW - unrelated donor hematopoietic cell transplant

UR - http://www.scopus.com/inward/record.url?scp=85058163262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058163262&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.09.004

DO - 10.1016/j.bbmt.2018.09.004

M3 - Article

C2 - 30292009

AN - SCOPUS:85058163262

VL - 25

SP - 270

EP - 278

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -